Aptose Upgraded to Trade on OTCQB Market
Aptose Biosciences (OTC: APTOF), a clinical-stage precision oncology company, announced its upgrade to the OTCQB Market effective July 1, 2025. The company, which develops tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML), will maintain its listing on the Toronto Stock Exchange (TSX) under the symbol "APS".
The OTCQB Venture Market caters to early-stage and developing U.S. and international companies that meet current reporting requirements and undergo annual verification and management certification processes.
Aptose Biosciences (OTC: APTOF), un'azienda di oncologia di precisione in fase clinica, ha annunciato il suo passaggio al mercato OTCQB a partire dal 1掳 luglio 2025. L'azienda, che sviluppa una terapia di prima linea a triplo farmaco a base di tuspetinib (TUS) per la leucemia mieloide acuta (AML) di nuova diagnosi, manterr脿 la sua quotazione alla Borsa di Toronto (TSX) con il simbolo "APS".
Il mercato OTCQB Venture 猫 rivolto a societ脿 statunitensi e internazionali in fase iniziale e in crescita, che rispettano i requisiti di rendicontazione attuali e sottopongono a processi annuali di verifica e certificazione della gestione.
Aptose Biosciences (OTC: APTOF), una compa帽铆a de oncolog铆a de precisi贸n en etapa cl铆nica, anunci贸 su ascenso al mercado OTCQB con efecto a partir del 1 de julio de 2025. La empresa, que desarrolla una terapia de primera l铆nea con triple medicamento basada en tuspetinib (TUS) para la leucemia mieloide aguda (LMA) reci茅n diagnosticada, mantendr谩 su cotizaci贸n en la Bolsa de Valores de Toronto (TSX) bajo el s铆mbolo "APS".
El mercado OTCQB Venture est谩 dirigido a empresas estadounidenses e internacionales en etapas tempranas y en desarrollo que cumplen con los requisitos actuales de reporte y pasan por procesos anuales de verificaci贸n y certificaci贸n de gesti贸n.
Aptose Biosciences (OTC: APTOF)電� 鞛勳儊 雼硠鞚� 鞝曤皜 膦呾枒頃� 須岇偓搿滌劀 2025雲� 7鞗� 1鞚�攵�搿� OTCQB 鞁滌灔鞙茧鞚� 靸來枼 臁办爼鞚� 氚滍憸頄堨姷雼堧嫟. 鞚� 須岇偓電� 靸堧 歆勲嫧霅� 旮夓劚 瓿垬靹� 氚表槇氤�(AML)鞚� 鞙勴暅 tuspetinib(TUS) 旮半皹鞚� 3欷� 鞎诫 1彀� 旃橂氩曥潉 臧滊皽頃橂┌, 韱犽韱� 歃濌秾瓯半灅靻�(TSX)鞐愳劀電� "APS"霛茧姅 鞁臣搿� 瓿勳啀 靸侅灔霅� 鞓堨爼鞛呺媹雼�.
OTCQB 氩れ矘 鞁滌灔鞚� 順勳灛 氤搓碃 鞖旉贝鞚� 於╈”頃橁碃 鞐半 瓴�歃� 氚� 瓴届榿 鞚胳 鞝堨皑毳� 瓯办箻電� 氙戈淡 氚� 甑牅 齑堦赴 雼硠 氚� 靹膘灔 欷戩澑 旮办梾鞚� 雽�靸侅溂搿� 頃╇媹雼�.
Aptose Biosciences (OTC : APTOF), une soci茅t茅 d'oncologie de pr茅cision en phase clinique, a annonc茅 sa mont茅e sur le march茅 OTCQB 脿 compter du 1er juillet 2025. La soci茅t茅, qui d茅veloppe une th茅rapie de premi猫re ligne 脿 triple m茅dicament bas茅e sur le tuspetinib (TUS) pour la leuc茅mie my茅lo茂de aigu毛 (LMA) nouvellement diagnostiqu茅e, conservera sa cotation 脿 la Bourse de Toronto (TSX) sous le symbole "APS".
Le march茅 OTCQB Venture s'adresse aux entreprises am茅ricaines et internationales en phase de d茅marrage et en d茅veloppement qui respectent les exigences actuelles de reporting et qui subissent des processus annuels de v茅rification et de certification de gestion.
Aptose Biosciences (OTC: APTOF), ein Unternehmen f眉r pr盲zisionsonkologische Therapien in der klinischen Phase, gab bekannt, dass es ab dem 1. Juli 2025 in den OTCQB-Markt aufsteigt. Das Unternehmen, das eine dreifach basierte Frontlinientherapie mit Tuspetinib (TUS) f眉r neu diagnostizierte akute myeloische Leuk盲mie (AML) entwickelt, wird weiterhin an der Toronto Stock Exchange (TSX) unter dem Symbol "APS" gelistet sein.
Der OTCQB Venture Market richtet sich an US-amerikanische und internationale Fr眉hphasen- und Wachstumsunternehmen, die die aktuellen Berichtspflichten erf眉llen und j盲hrlichen 脺berpr眉fungs- sowie Managementzertifizierungsprozessen unterliegen.
- Upgraded listing status to OTCQB Market may provide increased visibility and accessibility for U.S. investors
- Maintains dual listing on TSX and OTCQB markets
- None.
Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1st
SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (鈥�Aptose鈥� or the 鈥�Company鈥�) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced today that the Company has been upgraded to list for trading on the OTCQB Market under the ticker 鈥淎PTOF,鈥� in addition to the Company鈥檚 continued listing on the Toronto Stock Exchange (TSX) under the symbol 鈥淎PS鈥�. Trading on OTCQB begins today, July 1, 2025.
The OTCQB Venture Market is for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find AG真人官方-Time quotes and market information for the company on .
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company鈥檚 lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the Company鈥檚 plans, objectives, expectations and intentions and other statements including words such as 鈥渃ontinue鈥�, 鈥渆xpect鈥�, 鈥渋ntend鈥�, 鈥渨ill鈥�, 鈥渟hould鈥�, 鈥渨ould鈥�, 鈥渕ay鈥�, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. These risks and uncertainties include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 鈥淩isk Factors鈥� in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein.
These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
For further information, please contact
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
FAQ
When did Aptose Biosciences (APTOF) begin trading on the OTCQB Market?
What is Aptose Biosciences' (APTOF) main product in development?
What stock exchanges does Aptose Biosciences trade on?
What are the requirements for trading on the OTCQB Market?
